Ajanta Pharma announced a strong performance for the first quarter ended June 30, 2026, with consolidated revenue increasing by 25% to ₹1,626 crore. The company also declared an interim dividend of ₹32 per share, amounting to ₹399.79 crore. Profit after tax grew by 31% to ₹334 crore, reflecting healthy operational and financial execution.
Ajanta Pharma Reports Strong Q1 FY27 Results
Ajanta Pharma Limited has announced its financial results for the first quarter of the fiscal year 2026-27, ending on June 30, 2026. The company demonstrated robust growth, with consolidated revenue from operations reaching ₹1,626 crore, marking a significant increase of 25% compared to the previous year’s corresponding quarter (Q1 FY26), which stood at ₹1,303 crore.
Key Financial Highlights
- Profit Growth: Profit after tax for the quarter saw a substantial rise of 31%, reaching ₹334 crore, up from ₹255 crore in Q1 FY26.
- EBITDA Performance: Adjusted EBITDA (excluding forex loss) grew by 21% to ₹454 crore from ₹377 crore in the prior year’s quarter.
- Segment Growth: The Branded Generics segment showed a 13% growth, contributing ₹1,059 crore to the total revenue. US Generics reported a remarkable 57% increase, generating ₹487 crore, while Africa Institution business saw an 83% jump to ₹70 crore.
Dividend Declaration
In a significant move for shareholders, the Board of Directors has approved the payment of a 1st interim dividend of ₹32 per share for the financial year 2026-27. This dividend is based on a face value of ₹2 per share and amounts to a total payout of approximately ₹399.79 crore. The record date for this dividend has been set as August 5, 2026, with payment expected on or after August 18, 2026.
Operational Performance
The company highlighted its strong market position, noting that its India branded generic performance exceeded IPM growth by 36% as per IQVIA MAT June 2026. New launches contributed to higher growth, exceeding IPM by 76%, and volumes exceeded IPM by 40%. The company also showcased its presence in 34+ countries globally, with a strategic focus on Branded Generics.
Outlook and Strategy
Ajanta Pharma’s strategy continues to focus on new product launches, gaining market share in existing products, expanding into new countries and therapies, optimizing expenses, and enhancing digitalization across its operations. The company maintains a strong R&D pipeline and manufacturing capabilities, positioning it for continued growth in key markets.
Source: BSE
